

# Annual Report 2006-2207

---

## Working Group on Cardiovascular Pharmacology and Drug Therapy

---

### **Nucleus:**

Chairperson:	Dan Atar, Oslo, NO
Vice-chairperson:	Faiez Zannad, Nancy, FR
Past chairperson:	Ettore Ambrosioni, Bologna, IT
Treasurer:	Keld Kjeldsen, Copenhagen, DK
Secretary:	Kurt Stoschitzky, Graz, AT
Web editor:	Finn Gustafsson, Copenhagen, DK
Nucleus Members:	Ferenc Follath, Zurich, CH
	Brian NC Prichard, London, UK
	Luis Ruilope, Barcelona, SP
	Wiek van Gilst, Groningen, NL

### **VOTE:**

*(Elections during 2007) – none*

# Activities

**WG Annual Meeting(s):** none

## **Endorsed Meeting(s):**

- **Meeting 1:**

Name: Cardiovascular Clinical Trialists Forum  
Chair / organisation committee: Faiez Zannad  
(Co-organizer: Dan Atar)  
N° of participants: 800  
N° of exhibitors: 20

## **Publications / Guidelines / Scientific Papers**

### ***Submitted by the WG (not by individuals)***

*Please specify Topics & Authors (specify if ordinary member or nucleus members)*

- **Is your WG officially affiliated to a journal? Y**

Editor-in-Chief: Faiez Zannad and Pascal Bousquet  
Title: Fundamental and Clinical Pharmacology  
Contribution: Journal affiliated to our Working Group  
(Co-Editor (Faiez Zannad) is Vice-Chairman of our Working Group)

- **Position Papers / Consensus Documents**

1) Participation in Position Paper on "**Bleeding Events in ACS**" (D.Atar)  
Chairs: P. Gabriel Steg / Kurt Huber

- **Participation to guidelines writing / reviewing**

1) Review of ESC/AHA/ACC Guideline on Atrial Fibrillation

2) Participation in Guideline on "**Cardiovascular Disease Prevention**" (D.Atar)  
Chair: Ian Graham

3) Participation in Guideline "**Heart Failure**" (D.Atar)  
Chair: Kenneth Dickstein

4) Participation in Guideline "**Preoperative Cardiac Assessment**" (K.Kjeldsen)

5) Review of ESC/ESH Guideline on "**Arterial Hypertension**"

**Proposals for pre-arranged sessions at the ESC main congress and/or ESC Sub-specialty meetings**

**Proposal # 1 – ACCEPTED:**

**NEGATIVE DRUG TRIALS – DEAD ENDS OR NEW OPPORTUNITIES ?**

**Monday Sept 3, 14:00 – 15:30, Lisbon (Zone 1)**

**Proposal # 3 – ACCEPTED:**

**ACADEMIA INDUSTRY INTERACTIONS IN CLINICAL TRIALS**

**Sunday Sept 2, 14:00-15:30, Lisbon (Zone 1)**

**Proposal # 4 – ACCEPTED:**

**NEW ENDPOINTS AND ENDPOINT DEFINITION IN CV TRIALS**

**Sunday Sept 2, 16:30-18:00, Lisbon (Zone 1)**

**Proposal # 9 – ACCEPTED:**

**TRENDS IN ANTIPLATELET STRATEGIES**

**Monday Sept 3, 16:30 – 18:00, Lisbon (Zone 1)**

**Proposal # 10 – ACCEPTED:**

**Debate session:**

**CONTROVERSIES IN THE TREATMENT OF ARTERIAL HYPERTENSION**

*Proposed within this session, but now appearing separately in the program:*

**BETA-BLOCKERS AND DIURETICS:  
STILL FIRST-LINE TREATMENT IN ARTERIAL HYPERTENSION ?  
Monday Sept 3, 11:00-12:30, Stockholm (Zone 4)**

**ANGIOTENSIN-CONVERTING ENZYME INHIBITORS,  
ANGIOTENSIN RECEPTOR BLOCKERS, OR BOTH ?  
Monday Sept 3, 16:30 – 18:00, Warsaw (Zone 4)**

---

## **Future projects:**

- **Educational Autumn Meeting**, Vienna, AT, November 2007
- **Global CVCT Forum**, Cannes, FR, September 2008
- **Scandinavian Arrhythmia Spring Meeting**, Copenhagen, DK, June 2009

## **Finances:**

Balance sheet: EUR 3748,-

Sincerely yours

Prof. Dan Atar  
Chairman